Experimental Zika Vaccine to Begin Human Testing

FILE - In this Jan. 27, 2016, file photo, an Aedes aegypti mosquito is photographed through a microscope at the Fiocruz institute in Recife, Pernambuco state, Brazil. The World Health Organization says women who live in areas where Zika is spreading should consider delaying pregnancy, since there's no other sure way to avoid the virus' devastating birth defects. The WHO stops short of advising couples to put pregnancy on hold, as some countries battling the outbreak have. Instead, WHO spokeswoman Nyka Alexander says on June 9, that men and women who live in outbreak areas should be given information about the risks of Zika and told that delaying pregnancy is an option. AP Photo/Felipe Dana, File

 

WASHINGTON—An experimental vaccine for the Zika virus is due to begin human testing in coming weeks, after getting the green light from U.S. health officials.

Inovio Pharmaceuticals said Monday it received clearance from the Food and Drug Administration to begin early-stage safety tests of its DNA-based vaccine against the mosquito-borne virus. That puts the company ahead of researchers at the National Institutes of Health, who have said they expect to begin testing their own DNA-based Zika vaccine by early fall.

Inovio’s vaccine is intended to prime the immune system to fight Zika by introducing genetically-engineered material that mimics the virus. Inovio reports that animals tested with the vaccine developed antibodies and immune-system cells that attack Zika.

The NIH is working to develop a Zika vaccine by swapping out the genetic material from its experimental West Nile virus vaccine.

In this Feb. 11, 2016 file photo of aedes aegypti mosquitoes are seen in a mosquito cage at a laboratory in Cucuta, Colombia. AP Photo/Ricardo Mazalan, File